EPCLUSA 400 MG-100 MG TABLET
FDA nonproprietary name: velpatasvir and sofosbuvir
For 30 tablets
Pharmacies pay
$25,976.76 filed
30 × $865.89214 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$25,461.47 filed
30 × $848.71572 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.98× estimated
Medicare paid about what pharmacies pay.
Part D averages every strength and form sold under “Epclusa” / “Sofosbuvir/Velpatasvir” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$29,878.27 estimated
$25,976.76 + $3,896.51 (15%) + $5.00 fee per fill = $29,878.27
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
EPCLUSA 400 MG-100 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as velpatasvir and sofosbuvir, under the trade name “Epclusa”.
FDA gives its dosage form as tablet, film coated and its route as oral.
The labeler, the company named on the label, is Gilead Sciences, Inc.
FDA lists it under 2 Established Pharmacologic Classes: Hepatitis C Virus NS5A Inhibitor and Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor.
The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 61958-2201-01.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $25,976.76 for 30 tablets (30 × $865.89214 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $278.02579 per EA filed.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What NADAC measures · Why 30 tablets · NADAC explanation codes
The NDC
- 61958-2201-01 · Gilead Sciences, Inc. · $865.89214 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
1 other product in the NADAC file shares the FDA nonproprietary name velpatasvir and sofosbuvir with EPCLUSA 400 MG-100 MG TABLET.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| EPCLUSA 400 MG-100 MG TABLET this page | $865.89214 per EA filed | $848.71572 per EA filed |
| SOFOSBUVIR-VELPATASVIR 400-100 | $278.02579 per EA filed | $280.57703 per EA filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
What Medicare paid
Medicare Part D paid $25,461.47 for 30 tablets, at an average of $848.71572 per EA in 2024 (2024-01-01 to 2024-12-31) for “Epclusa” and “Sofosbuvir/Velpatasvir”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 31,431 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- Is a generic version available, and would it suit me? NADAC lists a generic with the same ingredient, strength and dosage form by FDA: SOFOSBUVIR-VELPATASVIR 400-100. Ask your pharmacist or prescriber; do not switch on your own.
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for EPCLUSA 400 MG-100 MG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Epclusa / Sofosbuvir/Velpatasvir: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.